-
Posted by
Two Blokes Jul 1 -
Filed in
Stock
-
5 views
HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax-efficient and more volatile. Active management and venture capital-style investing add agility but increase risk, with portfolio holdings changing frequently and a heavy biotech concentration. Total returns have been uninspiring, with NAV erosion, funding payouts, and sector underperformance, especially compared to broader healthcare funds like BME.
